# Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism

> **NCT01067365** · PHASE3 · COMPLETED · sponsor: **Repros Therapeutics Inc.** · enrollment: 104 (actual)

## Conditions studied

- Secondary Hypogonadism

## Interventions

- **DRUG:** Androxal
- **DRUG:** Androxal

## Key facts

- **NCT ID:** NCT01067365
- **Lead sponsor:** Repros Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2014-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01067365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01067365, "Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01067365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*